Cidara Therapeutics
CDTX
CDTX was delisted on the 6th of January, 2026.
0 hedge funds and large institutions have $0 invested in Cidara Therapeutics in 2026 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 249 closing their positions.
100% less funds holding
Funds holding: 255 → 0 (-255)
100% less funds holding in top 10
Funds holding in top 10: 28 → 0 (-28)
100% less capital invested
Capital invested by funds: $7.36B → $0 (-$7.36B)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 249
105.98% less ownership
Funds ownership: 105.98% → 0% (-106%)
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$743M |
| 2 |
BlackRock
New York
|
-$371M |
| 3 |
HI
HBK Investments
Dallas,
Texas
|
-$278M |
| 4 |
Fidelity International
Hamilton,
Bermuda
|
-$278M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$237M |
CDTX Hedge Fund Activity: Q1 2026 in Review
0 of the 8,182 institutional investors tracked by Wall St. Rank reported a position in Cidara Therapeutics (CDTX) for Q1 2026, worth a combined $0 — down 100% from $7.36B a quarter earlier.
Sellers outnumbered buyers: 249 funds closed out of CDTX and 0 opened new positions — a net loss of 249 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was RA Capital Management, exiting entirely with an estimated $743M sold.
- 0 institutional investors held Cidara Therapeutics (CDTX) as of Q1 2026, down from 255 in Q4 2025.
- Funds reported $0 of Cidara Therapeutics stock for Q1 2026, down 100% quarter-over-quarter.
- 0 funds opened new Cidara Therapeutics positions in Q1 2026 and 249 closed out, a net change of -249 holders.
- The largest Cidara Therapeutics seller in Q1 2026 was RA Capital Management, an estimated $743M sold.
Based on aggregated 13F filings for Q1 2026.